Gemistocytes in astrocytomas: are they a significant prognostic factor?

Area of Science:

• Neuro-oncology
• Cancer research
• Pathology

Background:

• Diffuse astrocytomas (WHO grades II and III) are primary brain tumors.
• Gemistocytic astrocytes are a subtype characterized by abundant cytoplasm.
• The prognostic significance of gemistocytes and specific protein markers remains debated.

Purpose of the Study:

• To evaluate the prognostic value of gemistocytic astrocytes, proliferation indices (MIB-1), and p53/bcl-2 immunoexpression in WHO grade II and III astrocytomas.
• To correlate these factors with clinical outcomes, including overall survival and progression-free survival.

Main Methods:

• Retrospective analysis of 39 patients with diffuse astrocytomas.
• Assessment of gemistocyte proportion, MIB-1 labeling index, and p53/bcl-2 expression.
• Correlation with overall survival and progression-free survival data.

Main Results:

• Mean gemistocyte proportion was 18.7%; mean proliferative index was 3.3%.
• p53 immunoexpression was found in 74.4% and bcl-2 in 100% of cases.
• No significant differences in survival were observed based on gemistocyte index, p53, bcl-2, MIB-1, age, or histological grade.

Conclusions:

• Gemistocytic astrocytes and evaluated protein markers (p53, bcl-2) do not appear to be significant prognostic factors in diffuse astrocytomas.
• The role of gemistocytes in astrocytoma progression requires further investigation.
• Current findings support recent literature questioning the prognostic value of gemistocytes.